Xuelian Cui1, Wei Niu2, Lingming Kong3, Mingjun He3, Kunhong Jiang3, Shengdong Chen4, Aifang Zhong5, Wanshuai Li6, Jim Lu6,7, Liyi Zhang3. 1. Department of Health Care, Changzhou Maternal & Child Health Care Hospital Affiliated with Nanjing Medical University, Changzhou, People's Republic of China. 2. Department of Rehabilitation, No. 102 Hospital of Chinese People's Liberation Army, Changzhou, People's Republic of China. 3. Prevention & Treatment Center for Psychological Diseases, No. 102 Hospital of Chinese People's Liberation Army, Changzhou, People's Republic of China. 4. Department of Neurology, No. 102 Hospital of Chinese People's Liberation Army, Changzhou, People's Republic of China. 5. Clinical Laboratory, No. 102 Hospital of Chinese People's Liberation Army, Changzhou, People's Republic of China. 6. Gopath Diagnostic Laboratory Co Ltd, No. 801, Changzhou, People's Republic of China. 7. Gopath Laboratories LLC, 1351 Barclay Blvd, Buffalo Grove, USA.
Abstract
AIM: This study aimed to determine whether circular RNA (circRNA) molecules in peripheral blood mononuclear cells (PBMCs) could be used as novel non-invasive biomarkers for major depressive disorder (MDD). MATERIALS & METHODS: Differentially expressed circRNAs were screened using an Arraystar Human CircRNA Array (which includes 13,617 human circRNAs) and qRT-PCR. Thirty MDD patients were randomly selected to retest the circRNA levels after 4-week and 8-week antidepressant regimens. RESULTS: Four differentially expressed circRNAs were identified between MDD patients and controls, and only down-regulated hsa_circRNA_103636 was significantly altered after the 8-week treatment in MDD patients. CONCLUSION: These results suggest that altered expression of hsa_circRNA_103636 in PBMCs is a potential novel biomarker for the diagnosis and treatment of MDD.
AIM: This study aimed to determine whether circular RNA (circRNA) molecules in peripheral blood mononuclear cells (PBMCs) could be used as novel non-invasive biomarkers for major depressive disorder (MDD). MATERIALS & METHODS: Differentially expressed circRNAs were screened using an Arraystar Human CircRNA Array (which includes 13,617 human circRNAs) and qRT-PCR. Thirty MDDpatients were randomly selected to retest the circRNA levels after 4-week and 8-week antidepressant regimens. RESULTS: Four differentially expressed circRNAs were identified between MDDpatients and controls, and only down-regulated hsa_circRNA_103636 was significantly altered after the 8-week treatment in MDDpatients. CONCLUSION: These results suggest that altered expression of hsa_circRNA_103636 in PBMCs is a potential novel biomarker for the diagnosis and treatment of MDD.
Entities:
Keywords:
biomarker; circRNA; early diagnosis; major depressive disorder; peripheral blood mononuclear cells; prognosis